Skip to main content
. 2009 Jul 9;30(5):494–535. doi: 10.1210/er.2009-0010

Figure 3.

Figure 3

The role of liver-derived IGF-I, the total pool of circulating endocrine IGF-I, and bone-derived IGF-I for body length and cortical bone mass. The bone length and the cortical bone mass in various IGF-I KO mouse models in relation to intact mice (A) and mice with total IGF-I inactivation (E, total IGF-KO) are summarized. The IGF-I KO models given in panels B–D are mice with liver-specific IGF-I inactivation (B, liver IGF-I KO); mice with dramatically reduced circulating endocrine IGF-I levels due to triple inactivation of liver IGF-I, total ALS, and total IGFBP-3 (C, endocrine IGF-I KO); and mice with bone-specific IGF-I inactivation (D, bone IGF-I KO). The total pool of circulating “endocrine” IGF-I in serum expressed as percentage of intact mice is given within parentheses for each mouse model. Blue X indicates inactivation/lack of this component. →, Unchanged compared with intact mice; ↓, reduced compared with intact mice but less reduced than in mice with total IGF-I KO; ↓↓, substantially reduced to the level seen in total IGF-I KO.